About Halozyme
Halozyme is a company based in San Diego (United States) founded in 1999. The company has 350 employees as of December 31, 2024. Halozyme has completed 3 acquisitions, including Antares Pharma, Elektrofi and Surf Bio. Halozyme offers products and services including ENHANZE, Auto-Injector, and Multi-Dose Pen Technologies. Halozyme operates in a competitive market with competitors including Jazz Pharmaceuticals, Insulet, C4 Therapeutics, Erasca and MiRagen, among others.
- Headquarter San Diego, United States
- Employees 350 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Halozyme Therapeutics, Inc.
-
Annual Revenue
$1.02 B (USD)22.44as on Dec 31, 2024
-
Net Profit
$444.09 M (USD)57.71as on Dec 31, 2024
-
EBITDA
$632.79 M (USD)49.8as on Dec 31, 2024
-
Latest Funding Round
$625 M (USD), Post-IPO
Aug 15, 2022
-
Investors
SVB
& 4 more
-
Employee Count
350
as on Dec 31, 2024
-
Investments & Acquisitions
Antares Pharma
& 2 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Halozyme
Halozyme is a publicly listed company on the NASDAQ with ticker symbol HALO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Halozyme
Halozyme offers a comprehensive portfolio of products and services, including ENHANZE, Auto-Injector, and Multi-Dose Pen Technologies.
Enhances drug administration for better patient treatment efficacy.
Provides automatic injection solutions for simplified medication delivery.
Offers multi-dose systems to improve drug dosing accuracy and convenience.
People of Halozyme
Unlock access to complete
Leadership Team
35 people
Software Development Team
27 people
Sales and Marketing
22 people
Senior Team
14 people
Product Management Team
9 people
Human Resources and Administration
6 people
Specialty Team
6 people
Finance and Accounting
4 people
Unlock access to complete
Funding Insights of Halozyme
Investors in Halozyme
Halozyme has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, Oxford Finance and Athyrium Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Venture debt firm focused on the life sciences sector
|
Locked | Locked | Locked | |
|
Corporate-backed venture capital firm focused on the healthcare sector
|
Locked | Locked | Locked |
Investor details for Halozyme
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Halozyme
Halozyme has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Antares Pharma, Elektrofi and Surf Bio.
Investment portfolio details for Halozyme
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for diabetes and other diseases are developed via biotechnology.
|
Locked | Locked | 2021 | Locked | |
|
Digital platform transforming the delivery of biologic medicines
|
Locked | Locked | 2016 | Locked | |
|
Existing drugs are reformulated using proprietary pen injectors.
|
Locked | Locked | 2000 | Locked |
Complete acquisition details for Halozyme
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Halozyme
Detailed financials for Halozyme
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Halozyme Comparisons
Peer comparison for Halozyme
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Halozyme
Halozyme operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Insulet, C4 Therapeutics, Erasca and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Wearable insulin infusion systems are developed for diabetes patients.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Halozyme
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Halozyme
Complete news archive for Halozyme
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Halozyme
Halozyme was founded in 1999 and raised its 1st funding round 7 years after it was founded.
Halozyme is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Helen Torley is the current CEO of Halozyme.
As of Dec 31, 2024, the latest employee count at Halozyme is 350.
Annual revenue of Halozyme is $1.02B as on Dec 31, 2024.
Halozyme was founded in 1999 and is headquartered in San Diego, United States. Operations focus on the biotechnology sector, where drug delivery technologies are developed to address various diseases. The lead product, ENHANZE, utilizes the proprietary enzyme rHuPH20 to enhance the delivery of injected drugs and fluids. Additionally, Hylenex, a recombinant endoglycosidase, is offered as an adjuvant to improve the dispersion and absorption of other injected drugs.
Halozyme's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Insulet.
Halozyme offers ENHANZE, Auto-Injector, and Multi-Dose Pen Technologies.
Yes, Halozyme is publicly traded on NASDAQ under the ticker symbol HALO.
Halozyme has made 3 acquisitions, including Antares Pharma, Elektrofi, and Surf Bio.
Halozyme has 5 investors. Key investors include SVB, Oxford Finance, Athyrium Capital Management, BioPharma Funds, and Roche.
The ticker symbol of Halozyme is HALO on NASDAQ.